Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for highest proportion of deal value, with each making up 32% of the aggregate Q4 financing dollars (see Exhibit 1).
Financing Quarterly Statistics, Q4 2024
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, October-December 2024
During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.
